Slide 1: Exchange filing cover letter: Q1 FY24 Investor Presentation
10th August, 2023 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Dalal Street, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: - Q1 FY24
Slide 2: Natco Pharma Limited Investor Presentation Q1 FY 2023-24
NATCO PHARMA LIMITED INVESTOR PRESENTATION Quarter I ending June 30 FY 2023-24 1
Slide 3: Disclaimer/Important Disclosure
DISCLAIMER/IMPORTANT DISCLOSURE THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background i
Slide 4: Key Highlights
KEY HIGHLIGHTS Diversified enterprise focused in pharmaceutical sector with presence across geographies - India, US and ROW. Strong brand position in domestic pharma segments • Well established player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer • Expa
Slide 5: Performance at a Glance
PERFORMANCE AT A GLANCE Financial Performance(1) (₹ million) Profitability Margins 28,117 43.2% 41.6% 22,424 22,247 37.0% 21,557 20,224 20,438 34.1% 32.9% 31.0% 29.0% 25.4% 22.8% 20.5% 10,402 17.7% 9,688 9,250 6,962 6,900 7,098 7,153 6,444 4,608 4,409 8.3% 3,625 1,700 FY 2018 FY 2019 FY 2020 FY 2021
Slide 6: Key Business Segments
KEY BUSINESS SEGMENTS DOMESTIC FORMULATIONS EXPORT FORMULATIONS SUBSIDIARIES API BUSINESS • Three key business segments: Oncology, • Focused on niche opportunities in the • Operations in Brazil, Canada, • 44 active DMFs(1) in the US with niche Specialty Pharma, Cardiology and US, Canada and emerging
Slide 7: US Market Focus - Complex Generics & Frontend
US MARKET FOCUS- COMPLEX GENERICS & FRONTEND KEY PRODUCTS IN THE PORTFOLIO (1) Predominantly focused on high-barrier-to-entry products that are typically characterized by one or more of the Therapeutic Segment Key Brand Molecule following: / Primary Indication ▪ Intricate Chemistry Revlimid
Slide 8: Resilient Domestic Pharma Business
RESILIENT DOMESTIC PHARMA BUSINESS OVERVIEW OF DOMESTIC PHARMA BUSINESS ONCOLOGY Three key business segments: Oncology, Pharma specialty and Cardiology & Diabetology One of the leaders in the branded oncology medicines in India Two decades of strong presence in oncology segment with 54(1) in Focus
Slide 9: Expanding ROW Presence
EXPANDING ROW PRESENCE CANADA Strong portfolio with 30+ products including Oncology, anti-viral, cardiovascular and CNS therapies Amongst top 10 generic companies by sales revenue in Canada 25 approvals in place Highest market share of Nat-Lenalidomide in this molecule Launched Nat-Pomalidomide, Nat
Slide 10: API Facilities
API FACILITES Strategically important business – develops APIs primarily for third party sales and also for captive consumption MEKAGUDA Portfolio of 44 (1) active US DMFs with niche products under development TELANGANA Oncology API's and speciality Focus on complex oncology molecules. Other therape
Slide 11: Formulation Facilities
FORMULATION FACILITIES INTERNATIONAL MARKETS DOMESTIC MARKETS KOTHUR VISAKAPATNAM NAGARJUNASAGAR* GUWAHATI DEHRADUN TELANGANA ANDHRA PRADESH TELANGANA ASSAM UTTARAKHAND Oral and solid dosages including Solid oral tablet and capsule Oncology, Antibiotics and Tablets, Capsules Tablets, Capsules dry po
Slide 12: R&D Capabilities
R&D CAPABILITIES R&D Expense (₹ in million) 2,500 12% 14.0% R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments 12.0% 2,000 9.3% 9.1% 8.7% 10.0% 7.8% 8% 1,500 8.0% 2,267 6.0% Two research facilities with capabilities across synthetic chemistry, nan
Slide 13: Crop Health Sciences
CROP HEALTH SCIENCES Leveraging strong Techno-Legal expertise in Pharma to drive business in Agro-Chemical segment. Manufacturing Facilities include a Technical (Active Ingredient) and Formulation asset, located in the state of Andhra Pradesh. Operate additional leased facilities, especially to supp
Slide 14: Consolidated Financials
CONSOLIDATED FINANCIALS CONSOLIDATED PROFIT & LOSS (₹ IN MILLION) CONSOLIDATED PROFIT & LOSS (₹ IN MILLION) Year ended As at As at S.No. Particulars 31 March 2023 31 March 2022 31 March 2023 31 March 2022 Audited Audited (Audited) (Audited) I Assets (1) Non-current assets Income (a) Property, plant
Slide 15: Quarterly Financial Summary
QUARTERLY FINANCIAL SUMMARY SEGMENTAL BREAKDOWN (₹ IN MILLION) CONSOLIDATED FINANCIAL RESULTS (₹ IN MILLION) Revenue Division Q1FY24 Q1FY23 FY 23 FY22 Q1FY24 Q1FY23 FY 23 FY22 A) API Revenue(1):- 751 508 2,103 2,481 Total Revenues 11,602 9,189 28,117 20,438 B) Formulation:- EBITDA 5,477 4,296 10,402
Slide 16: Investor relations contact
Email: ir@natcopharma.co.in Phone: 040-2354 7532 15